BALTIMORE, April 3 /PRNewswire/ -- Alba Therapeutics Corporation today announced the successful completion of multidose safety studies in normal volunteers, concluding Phase I trials for its lead compound, oral AT-1001. Combined with Alba’s previous single dose study and Phase Ib demonstration of intestinal permeability decrease in gluten-challenged celiac disease patients, this safety data brings the company closer to its goal of delivering an autoimmune treatment based upon modulation of mucosal barrier function. “We look forward to filing a diabetes IND and to entering Phase II trials for celiac disease as early as this summer,” stated Dr. Blake Paterson, CEO of Alba, “and continue to develop the breadth of our core technology platform for multiple applications.”
About Celiac Disease
Celiac disease (“CD”) is a T-cell mediated auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, CD affects approximately 3 million Americans. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.
About Type I Diabetes
Type I diabetes (“T1D”) is an autoimmune disease that results in the destruction of the insulin producing cells of the pancreas, the islet beta cells. Current treatment of T1D is limited to the administration of insulin and other medications to treat the consequence of diabetes, elevated blood sugar and the complications thereof. The inability to treat the cause of T1D has been the key obstacle to the freeing patients from the yoke of this disease.
About Alba
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics and drug delivery adjuvants based on the zonulin pathway. Alba’s lead molecule, AT-1001, is targeted towards the treatment of celiac disease and other auto-immune illnesses.
Contact: Heather Bakalyar of Alba Therapeutics, +1-410-319-0780 ext. 110
Alba Therapeutics Corporation
CONTACT: Heather Bakalyar of Alba Therapeutics, +1-410-319-0780 ext. 110
Web site: http://www.albatherapeutics.com//
